July 8, 2026
Biocytogen and Whitehawk partner to develop ADCs
Biocytogen and Whitehawk Therapeutics are set to develop bispecific antibody-drug conjugates (BsADCs), as part of a global partnership.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







